Segun indica Oryzon en su informe..
Cáncer de mama
La LSD1 podría ser una diana terapéutica útil en varios tipos de cáncer de mama; en particular, los inhibidores de la LSD1 podrían tener utilidad en el tratamiento de cánceres ER- -negativo para los que las opciones terapéuticas son mínimas, basado en datos publicados en la literatura científica por terceros. Por estas razones diversos grupos han estudiado la relación entre LDS1 y ER- y han demostrado en publicaciones científicas que la inhibición de la desmetilación producida por LSD1 reduce o elimina la capacidad de unión de ER- a las regiones de control de los genes de respuesta al estrógeno y provoca un fuerte efecto anti-proliferativo en las células del cáncer de mama. De hecho, la terapia combinatoria de anti-estrógenos con inhibidores de la LSD1 mostró un efecto terapéutico significativamente mejor en comparación con la terapia endocrina sola para inhibir el crecimiento celular. Se ha sugerido finalmente que los inhibidores de LSD1 podrían restaurar la sensibilidad de las células de cáncer de mama resistentes a la terapia con el tratamiento hormonal. La compañía SALARIUS está desarrollando su inhibidor LSD1 (Seclidemstat) en cáncer de mama TNBC y ovario.
5. Conclusions
In conclusion, our data show that LSD1 is a main regulator of the key properties of bCSCs, as it plays an important role in their self-renewal and tumor-initiation capacity in vitro and in vivo. We also demonstrated that LSD1 mediates drug resistance in breast cancer cells. Our data suggest that this may be due to the fact of its role in the maintenance of a pool of functional bCSCs. We also provide strong experimental data that LSD1 is a prime candidate for the development of CSC-targeted therapies. Lysine-specific demethylase 1 inhibitors could be used in combination therapeutic schemes along with anti-cancer drugs to target all tumor subpopulations and achieve complete tumor elimination in breast cancer
Este estudio dice que LSD1 inhibitor puede ser utilizado en combinacion con quimioterapia con cualquier tioo de cancer de pecho..por que?
Our experiments showed a synergistic action between the anti-cancer drugs and the LSD1 inhibitors at the dose-ratios tested. Another striking finding was that the drugs alone had no effect or caused a small enrichment of the CSC subpopulation, in agreement with our previous findings. Administration of an LSD1 inhibitor was necessary for the targeting of these cells. In the protocol used, the parallel administration of LSD1 inhibitors and drugs did not have a synergistic effect on the number of CSCs. It seems that the inhibitor by itself was sufficient to produce the desired effect. However, as stated above, monotreatment with the inhibitors was not successful against the entire tumorsphere, indicating their inefficiency against more differentiated cancer cells. Therefore, both classes of agents are needed to achieve complete tumor (sphere) elimination.